Beijing Tiantan Biological Products Co., Ltd.

It earns money through one-time sales of its products rather than through subscriptions, licensing arrangements, or recurring service fees, with domestic revenue recognized once goods reach the buyer and are confirmed received, and export revenue recognized once customs clearance and payment occur. A small number of related product families dominate that revenue rather than the wider catalog, and the underlying business has recorded a positive net profit in every year for which CompanyGraph holds statements.

Its scale is set less by demand than by two things that must grow together: how much plasma its licensed collection centers can gather, and how much of that plasma its own regulated production sites can convert into finished product, since national law bars it from having its products made under contract elsewhere. A large share of earnings has been kept inside the business rather than paid out, alongside a multi-year run of consistent profit, which points toward physical expansion being funded from within the business, and its equity base sits toward the higher end of its industry's typical range. This ties growth to licensed physical capacity rather than to replicating a low-cost standard unit or growing a network of users.

Its own filings identify healthy human plasma as the essential input, gathered through centers it holds licenses to operate rather than purchased on an open market, and name a small set of related businesses supplying materials, services, equipment and energy alongside it. Its stated risks center on that plasma supply and on the difficulty of getting new collection centers licensed, though the company does not describe itself as dependent on any small group of outside suppliers. CompanyGraph's mapping of its position in the wider economy also shows it draws from fewer supplying industries than the number of industries that draw from it.

Its products reach hospitals, clinics and retail pharmacies mainly through regional distributors that government tenders select and price, rather than through direct sale to those end buyers, with a smaller amount sold abroad through separate distributors. It also states a role in maintaining part of a national reserve of these products. The company does not describe a concentrated reliance on any small set of named customers, and CompanyGraph's mapping shows it supplies into more industries than the number it depends on.

The company states its own advantages include the scale of its production network, the size and reach of its licensed plasma-collection centers, the breadth of its approved product list, and its position under a central state-owned parent, and it describes itself as holding the leading domestic position in plasma-center count and collection volume. Separately, CompanyGraph's mapping shows this company shares its basic economic shape, earning production revenue only after clearing a long regulatory approval process, with a large group of other companies, so that shape on its own is not unusual. Whether competitors could replicate the company's specific licensed network or approval history is not something CompanyGraph measures here.

The company's own account of what limits its growth centers on the supply of raw material, not primarily the regulatory approval gate that shapes its wider industry: it states that healthy human plasma is difficult to source, that government approval of new collection centers is becoming stricter, and that the volume of plasma it can collect may grow more slowly than the production capacity it is building. It separately names the long, costly and uncertain cycle of developing and gaining approval for new products as a constraint of its own. Together these describe a business bound first by a licensed, regulated input, with the approval process for new products acting as a second, distinct limit.

The company's own risk disclosures list national policy risk first, ahead of product-safety risk, the regulatory risk attached to its plasma centers, the risk of insufficient raw-material supply, a decline in product gross margin, and product-development risk, in that stated order. Because its production depends on plasma gathered under government-issued licenses and its products cannot legally be made under contract elsewhere, a tightening of licensing terms or a shift in tender policy would act directly on the business rather than on a part of it that could be routed around. The company states it has no major litigation or arbitration pending and does not describe a concentrated dependence on a small number of named customers or suppliers.

Its own filings name national health policy as the pressure it lists first, ahead of product-safety risk, the regulatory risk around its plasma centers, raw-material supply risk, margin pressure and product-development risk. Several layers of approval sit above its operations at once: provincial health authorities license its plasma-collection sites, the national drug regulator governs manufacturing, and a batch cannot be sold unless it passes mandated release testing. It is also controlled through a state pharmaceutical parent that itself sits under the state's asset-management authority, so government ownership and government regulation act on it through two separate channels. In the disclosures CompanyGraph has reviewed, it reports no material litigation, sanctions, or currency exposure.